Revised SPC: Ultomiris (ravulizumab) 300 mg concentrate for solution for infusion

Various sections updated with information relating to new indication - treatment of patients with a body weight of ≥10 kg with atypical haemolytic uremic syndrome who are complement inhibitor treatment-naïve or have received eculizumab for ≥3 months and have evidence of response.


electronic Medicines compendium